Cure Today5d
Sasanlimab Improves Event-Free Survival for Some With Bladder Cancer
The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
Hosted on MSN5d
Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...
BioWorld8d
Pfizer’s PD-1 inhibitor hits endpoint in BCG-naïve bladder cancer
The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...
Zacks.com on MSN2d
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...
Joplin Globe8d
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer ...